An Immunodominant Epitope-Specific Monoclonal Antibody Cocktail Improves Survival In A Mouse Model Of Staphylococcus Aureus Bacteremia
JOURNAL OF INFECTIOUS DISEASES(2021)
摘要
To date, no vaccine or monoclonal antibody (mAb) against Staphylococcus aureus has been approved for use in humans. Our laboratory has developed a 5-antigen S. aureus vaccine (rFSAV), which is now under efficacy evaluation in a phase 2 clinical trial. In the current study, using overlapping peptides and antiserum from rFSAV-immunized volunteers, we identified 7 B-cell immunodominant epitopes on 4 antigens in rFSAV, including 5 novel epitopes (Hla(48-65), IsdB(402-419), IsdB(432-449), SEB78-95, and MntC(7-24)). Ten immunodominant epitope mAbs were generated against these epitopes, and all of them exhibited partial protection in a mouse sepsis model. Four robust mAbs were used together as an mAb cocktail to prevent methicillin-resistant S. aureus strain 252 infection. The results showed that the mAb cocktail was efficient in combating S. aureus infection and that its protective efficacy correlated with a reduced bacterial burden and decreased infection pathology, which demonstrates that the mAb cocktail is a promising S. aureus vaccine candidate.
更多查看译文
关键词
methicillin-resistant Staphylococcus aureus, immunodominant epitope, monoclonal antibody, bacteremia
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要